Navigation Links
VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
Date:1/7/2008

associated with this disease. Despite currently available medications that treat the conditions that increase the risk of these events, these therapies do not treat the underlying inflammation."

The company provided the following specific update for each of its three Phase 2 clinical trials:

FDG-PET Study

The FDG-PET trial is enrolling approximately 50 patients following a heart attack into a 24 week randomized, double blind, placebo-controlled study. Enrollment is expected to be complete during 2008 and data is expected in the first half of 2009. Endpoints in the study include reduction in plaque inflammation following dosing with VIA-2291 as measured with FDG-PET, as well as assessment of standard biomarker measurements of inflammation. The use of state-of-the art FDG-PET imaging technology provides a new and important methodology for measuring the effect of VIA-2291 in reducing vascular inflammation.

"We are pleased with the progress of our clinical program and the commencement of our third Phase 2 trial to directly demonstrate the impact of VIA-2291 on inflammation in patients with advanced atherosclerotic disease," said Adeoye Olukotun, MD, chief medical officer of VIA. "The data from this study, in combination with our other two trials, is designed to directly assess the safety, mode of action and clinical activity of VIA-2291 to reduce vascular inflammation, and therefore, the risk of major adverse cardiovascular events."

The first patient was randomized to treatment at Massachusetts General Hospital in Boston. Mount Sinai Heart in New York City is also participating in the study.

Carotid Endarterectomy (CEA) Study

VIA has enrolled approximately 40 patients in the CEA study as planned, and is expanding enrollment to gather additional data by taking advantage of additional patients currently in the screening and patient recruitment process. VIA plans to enroll approximately 50 patients and expects to report data
'/>"/>

SOURCE VIA Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... has announced the addition of the "Investigation ... report to their offering. Developed by ... of Novolog) is an important drug for the ... aspart, as a fast- acting insulin analog, starts ...
(Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; ... MYL ) shareholder vote regarding its planned unsolicited ... Mylan,s offer to Perrigo shareholders have always been, and ... reflection of the value available to Perrigo shareholders, and ... has allowed its shareholders to consider," said Joseph ...
(Date:8/28/2015)... -- The report "Eubiotics Market by Type (Probiotics, Prebiotics, Organic ... & by Region ( North America , ... Rest of the World) - Global Trends and Forecast to ... valued at USD 4.62 Billion in 2014 and is projected ... of 7.4% from 2015 to 2020. Browse ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... Alcoa (NYSE: AA ) today announced a ... CDXS ) and CO2 Solution Inc. (TSX-V: CST), focused ... neutralizing the material to create a commercially viable product. ... world,s leading aluminum producer and will be funded by Alcoa ...
... a new market research report is available in its catalogue: ... http://www.reportlinker.com/p0470752/World-In-Vitro-Diagnostics-Market.html Global ... The Freedonia Group projects world demand for in vitro diagnostic ... in 2014. Based on the advanced nature of medical delivery ...
Cached Medicine Technology:Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products 2Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products 3Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products 4Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products 5Reportlinker Adds World In Vitro Diagnostics Market 2Reportlinker Adds World In Vitro Diagnostics Market 3Reportlinker Adds World In Vitro Diagnostics Market 4Reportlinker Adds World In Vitro Diagnostics Market 5Reportlinker Adds World In Vitro Diagnostics Market 6Reportlinker Adds World In Vitro Diagnostics Market 7Reportlinker Adds World In Vitro Diagnostics Market 8Reportlinker Adds World In Vitro Diagnostics Market 9
(Date:8/28/2015)... ... August 28, 2015 , ... ... Addictions specialist, Dr. James Strawbridge, gives a new approach on solutions in his ... begin with the employer and employees getting together for meaningful group meetings. "This ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... loyalty at a low cost. Personalized with practice contact information and logos, Calendars ... Dental offices can also incorporate Calendars into seasonal mailings, thank you and welcome ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... for those seeking to go deep sea diving. The act of recreational ... decompression sickness; for these reasons, it is vital that all recreational and professional ...
(Date:8/28/2015)... ... August 28, 2015 , ... Popular review ... millionaire dating sites . According to the listings, MillionaireMatch.com bags ... this category. , A spokesperson of Top5MillionaireDatingSites.com said, “This website has ...
(Date:8/28/2015)... ... ... Inc. magazine today ranked PREVENT Life Safety No. 3660 on its ... The list was unveiled online at Inc.com and is the most competitive crop in ... ranks higher on the list than any other company in their industry. , PREVENT ...
Breaking Medicine News(10 mins):Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Top5MillionaireDatingSites.com Publishes Its First List of Reviews of the Best Millionaire Dating Sites 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2
... generic drugs will get them into consumers, hands quicker, but ... marketing researcher has found. A mathematical model created by ... the chances of getting there first and commanding the best ... Ching is an associate professor of marketing at the University ...
... By Kathleen Doheny HealthDay Reporter , MONDAY, Feb. ... levels of exposure to a substance found in a commonly ... a mental developmental test at 3 years of age than ... at all, new research says. Megan Horton, a postdoctoral ...
... , PHILADELPHIA - So-called barrier sites -- the skin, ... allergens, pollutants, viruses, bacteria, and parasites. Understanding how the ... for understanding such inflammatory diseases as asthma, psoriasis, IBD, ... body,s barriers. David Artis, PhD, professor of ...
... , MONDAY, Feb. 7 (HealthDay News) -- The ... along with the economy, statistics released Monday suggest. ... performed in the country, up five percent from 2009, ... nearly 1.6 million cosmetic surgical procedures and 11.6 cosmetic ...
... PICK: Profiling malaria-causing parasites The majority of ... parasite Plasmodium falciparum . Most at risk are young ... led by Patrick Duffy, at the National Institutes of Health, ... falciparum parasites in such a way that they are ...
... gambling rates continue to rise, University of Missouri researchers ... as an effective and inexpensive way for people with ... Matthew Martens, associate professor of Educational, School and ... his team of researchers received a $172,500 grant ...
Cached Medicine News:Health News:Prenatal Exposure to Pesticides May Harm Kids' Development 2Health News:As Economy Picks Up, So Do Number of Nips & Tucks 2Health News:JCI online early table of contents: Feb. 7, 2011 2Health News:JCI online early table of contents: Feb. 7, 2011 3Health News:JCI online early table of contents: Feb. 7, 2011 4Health News:JCI online early table of contents: Feb. 7, 2011 5Health News:JCI online early table of contents: Feb. 7, 2011 6Health News:JCI online early table of contents: Feb. 7, 2011 7Health News:Simple feedback could be effective therapy for addictive behaviors 2
Caspar Curette, 250 mm, 10"....
Bone Curette, 160 mm...
Bone Currettes...
Townsend is a endocervical stainless-steel curette with round tapered tip....
Medicine Products: